for patients
understanding Hyperinsulinism
Focused on substantially improving the quality of life for individuals living with hyperinsulinism.
There are multiple forms of hyperinsulinism (HI) that can result in hypoglycemia. Congenital HI primarily affects infants and children, while tumor HI generally impacts adults with insulinomas or non-islet cell tumors (NICT). Despite the persistent and dangerous nature of hypoglycemia in these populations, today’s treatment options are limited, often ineffective, and poorly tolerated.
This critical gap leaves many patients vulnerable to recurrent, unpredictable hypoglycemic lows, highlighting the urgent need for innovative, effective therapies.
Congenital Hyperinsulinism
Tumor Hyperinsulinism
Ersodetug is an insulin receptor modulating antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any form of HI.
When no approved treatments are available, some patients may qualify for compassionate use, also called an Expanded Access Program (EAP). Rezolute supports EAPs to help patients with serious conditions access investigational therapies like ersodetug.
Our EAP is designed for patients who benefited from ersodetug during clinical trials and wish to continue treatment, or for those with severe, frequent low blood sugar due to high insulin levels who have no other options.
If you think you may qualify, talk to your healthcare provider, or contact us at: [email protected]
patient voices
This video, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “prove,” “potential,” “seek,” “strive,” “try,” or future or conditional verbs such as “predict,” “could,” “may,” “likely,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Viewers are cautioned not to place undue reliance on these forward-looking statements, which speak only as an individual patient. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov.
You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. This video shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.